Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Hansoh Pharmaceutical Group Company Ltd. have established an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for its selected fully human antibody molecules against a designated target for development, manufacturing and commercialization globally.
South Korean biotech Pinotbio Co. Ltd. inked a $250 million (₩320 billion) licensing deal with Princeton, N.J.-based Conjugatebio Inc. to develop 10 antibody-drug conjugate (ADC) targets with Pinotbio’s ADC platform technology. The deal announced on Dec. 21 adds to a previous agreement between the two companies last year. Pinotbio and Conjugate first teamed up to discover and develop five ADC targets in June 2022.
Innovent Biologics Inc. has in-licensed LG Chem Ltd.’s tigulixostat (LC-350189), a late-stage non-purine xanthine oxidase inhibitor for managing chronic hyperuricemia in patients with gout, in a deal worth up to $95 million.
Innovent Biologics Inc. has in-licensed LG Chem Ltd.’s tigulixostat (LC-350189), a late-stage non-purine xanthine oxidase inhibitor (XOI) for managing chronic hyperuricemia in patients with gout, in a deal worth up to $95 million.
Pfizer Inc. and Clear Creek Bio Inc. have entered into a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19.
Six months after a merger deal fell through, leaving the company to face possible bankruptcy, Therapeuticsmd Inc. agreed to license U.S. commercialization rights for its women’s health care products to Australian firm Mayne Pharma Group Ltd. in exchange for $140 million up front plus milestone and royalty payments.
Six months after a merger deal fell through, leaving the company to face possible bankruptcy, Therapeuticsmd Inc. agreed to license U.S. commercialization rights for its women’s health care products to Australian firm Mayne Pharma Group Ltd. in exchange for $140 million up front plus milestone and royalty payments.
Blue Water Vaccines Inc. has signed an exclusive, global license agreement for the development of a live attenuated, oral chlamydia vaccine candidate from The University of Texas (UT) Health San Antonio. Developed at UT Health San Antonio, the novel vaccine candidate utilizes a live attenuated chlamydia strain, Chlamydia muridarum.
RSS
